Abstract:Objective To evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myeloid leukemia (CML) and analyze the prognostic factors influencing the long term survival. Methods One hundred and eighteen CML patients with a median follow-up period of 41 months were enrolled, including 88 in chronic phase, 8 in accelerate phase and 22 with blast crisis. Eighty three patients received related donor allo-HSCT and 35 with unrelated donor allo-HSCT. Thirty six patients received total body irradiation and cyclophosphamide (Cy) as preconditioning regimen and 82 patients received modified BuCy (busulfan,Cy, cytosine arabinoside) protocal. For graft-versus-host disease (GVHD) prophylaxis, ciclosporine (CsA) and methotrexate (MTX) were used in patients receiving human leucocyte(HLA) fully matched sibling donor (MSD) transplants and CsA, MTX, antihuman thymocyte globulin (ATG) and mycophenolate (MMF) were used in patients receiving HLA not fully matched related donor (MRD) and unrelated donors (URD) transplants. Cox regression model was used to evaluate the prognostic factors of chronic myeloid leukemia (CML) and Kaplan and Meier survival analysis model was used to estimate the cumulative overall survival (OS) and the disease free survival (DFS). Results Except the three cases died of preconditioning related toxicity, all others got hematopoitic reconstruction. Five years cumulative infection rate was 42.6%, CMV antigenemia was 41.6%. The cumulative incidence of Ⅱ-Ⅳ acute GVHD was 33.3%; 23.1% in MSD and 46.9% in MRD/URD (P=0.01). One year cumulative incidence of chronic GVHD was 47.8%; 51.4% in MSD and 42.2% in MRD/URD, respectively (P=0.260). The 5-year cumulative relapsing rate was 17%; 12.5% in MSD and 23.9% in MRD/URD (P=0.228). Five years cumulative OS and DFS rates were 69.5% and 62.6%, respectively; 78.5% and 72.7% in MSD, 57.2% and 48.3% in MRD/URD, respectively (P=0.018, P= 0.017). Five years OS and DFS rate in chronic phase and accelerate/blast phase were 79.9%, 36.7% and 72.4%, 32.6%, respectively (P<0.001). Multivariate Cox model analysis showed that grade Ⅱ-Ⅳ acute GVHD, HLA mismatch and time from diagnosis to transplantation ≥ 1 year were independent risk factor for OS. Accelerate/blast phase and MTX+CsA+ ATG or MMF for GVHD prophylaxis were risk factors for DFS. Conclusions Patients had transplantation done within one year from diagnosis,low grade acute GVHD, HLA identical sibling donor and chronic phase had better prognosis. The main risk factor of death is GVHD.

[The Clinical Analysis of Allogeneic Hematopoietic Stem Cell Transplantation from Human Leukocyte Antigen-Identical Siblings in 95 Patients with Myelodysplastic Syndrome].

Hla-Haploidentical Stem Cell Transplantation for Malignant Hematological Diseases Using G-Csf Mobilized Bone Marrow and Peripheral Blood Stem Cells

[Allogenic Stem Cell Transplantation from Genotypically HLA-identical Siblings for 30 Patients with Myelodysplastic Syndromes].

Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Intermediate-Risk Acute Myeloid Leukemia Adult Patients in First Complete Remission: A Meta-Analysis of Prospective Studies.

Clinical efficacy of allogeneic hematopoietic stem cell transplantation on myelodysplastic syndrome

The Clinical Analysis of Haploidentical Stem Cell Transplantation in Myelodysplastic Syndrome-Associated Acute Myeloid Leukemia

HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome

[Clinical Efficacy of the MDS Patients Treated by Allo-HSCT].

Optimizing Timing and Preparation for Allogeneic Hematopoietic Stem Cell Transplantation in Higher-Risk Myelodysplastic Syndromes

Unmanipulated haploidentical hematopoietic stem cell transplantation for children with myelodysplastic syndrome

Clinical analysis of 104 patients with hematological malignancy after allogeneic hemotopoietic stem cell transplantation]

[Analysis of Clinical Efficacy and Prognosis in 83 Cases Receiving Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies].

Comparison of Three Different Types of Donor Hematopoietic Stem Cell Transplantation for Intermediate and High-Risk Myelodysplastic Syndrome

[Effects and Prognostic Factors of HLA-matched Sibling Donor Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia].

Curative effect analysis of allogeneic hematopoietic stem cell transplantation for 150 patients with hematological malignancies

Haploidentical Hematopoietic Stem Cell Transplantation Without In Vitro T-Cell Depletion For The Chronic Myeloid Leukemia: Improved Outcomes In Patients With Accelerated Phase And Blast Crisis Phase

Long-term follow-up of allogeneic hematopoitic stem cell transplantation for patients with chronic myeloid leukemia

[Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia]

Haplo-Identical Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndrome: Similar Survival in Comparison with HLA-Identical Siblings: Multi-Center, Prospective Study

Clinical contrasting study on hematopoietic stem cell transplantation from HLA-identical sibling and partially HLA-mismatched related donors]

Clinical Study on Haploid HLA-haploidentical Hematopoietic Stem Cell Transplantation for Treatment of Malignant Hematological Disease